Mailisheng (Aggrastin α) – Neutropenia | HongKong DengYue Medicine

  • Generic Name/Brand Name: ​Aggrastin α / Mailisheng®
  • Indications: Neutropenia
  • Dosage Form: ​Injection
  • Specification: 20 mg × 1 vial/box

Aggrastin α Application Scope

Indicated for adult patients with non-myeloid malignancies undergoing chemotherapy that is likely to cause febrile neutropenia, to reduce the incidence of infections manifested as febrile neutropenia.

mailisheng aggrastin α
mailisheng aggrastin α

Aggrastin α Characteristics

  • Ingredients: Recombinant human granulocyte colony-stimulating factor (G-CSF) α fused with human serum albumin (HSA).

  • Properties:​ A fourth-generation long-acting G-CSF utilizing HSA fusion technology to extend the half-life in the body, reducing dosing frequency and improving patient compliance.

  • Packaging Specification:​ 20 mg per vial.

  • Storage:​ Store at 2–8°C, protected from light.

  • Expiry Date: Refer to the packaging label.

  • Executive Standard: ​Chinese Pharmacopoeia 2020 Edition.

  • Approval Number: National Drug Approval No. H20250031.

  • Date of Revision: May 2025.

  • Manufacturer: Qilu Pharmaceutical Co., Ltd.

Guidelines for the Use of Mailisheng

  • Dosage and Administration:

    • Recommended Dose: 500 μg/kg, administered subcutaneously on the third day after the end of the chemotherapy cycle.

    • Administration: Subcutaneous injection.

    • Missed Dose:​ If a dose is missed, administer as soon as possible. Consult a healthcare professional for guidance.

  • Adverse Reactions:

    • Common Adverse Reactions:

      • Injection site reactions

      • muscle pain

      • fatigue

    • Serious Adverse Reactions:

      • Allergic reactions

      • chest pain

      • difficulty breathing

  • Contraindications: Contraindicated in patients with known hypersensitivity to this product or its components.

  • Precautions:

    • Assess the patient’s history of allergies to G-CSF-like drugs before use

    • regularly monitor the injection site.

Aggrastin α Interactions

  • Currently, there is no specific data available regarding drug interactions.
  • During treatment with this product, avoid concurrent use with other G-CSF-like drugs to reduce the risk of adverse reactions.

 

Note:

  • If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
  •  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.
Contact Us
Contact Form Demo